| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
AMPK (AMP-activated protein kinase). AMPK activator 12 is a potent AMPK activator. It also induces GDF15 expression. AMPK is a key energy sensor that regulates cellular metabolism, autophagy, and cell growth. GDF15 is a cytokine involved in energy homeostasis and cancer.
|
|---|---|
| ln Vitro |
AMPK activator 12 demonstrates potent activation of AMPK in biochemical and cellular assays. It increases GDF15 protein levels in human hepatic cells. The compound's dual activity as an AMPK activator and GDF15 inducer makes it a valuable tool for studying energy metabolism and cancer pathways. Detailed EC50 values have not been disclosed.
|
| ln Vivo |
In vivo activity of AMPK activator 12 has not been extensively characterized in published literature. The compound is primarily used as an in vitro research tool. In vivo studies would be needed to evaluate its therapeutic potential in cancer or metabolic disease models. Currently, no in vivo efficacy data have been reported in peer-reviewed literature.
|
| Enzyme Assay |
In vitro enzyme assays for AMPK activation are performed using recombinant AMPK enzyme and a suitable peptide substrate (e.g., SAMS peptide) in the presence of ATP. AMPK activator 12 is incubated at varying concentrations with the enzyme and substrate. Phosphorylation is detected by radioactivity (³³P-ATP) or by fluorescence-based methods (e.g., ADP-Glo). EC50 values are calculated from dose-response curves. For GDF15 induction, ELISA or Western blot is used.
|
| Cell Assay |
Cells (e.g., human hepatic cells, hepatocytes, or cancer cell lines) are cultured and treated with AMPK activator 12 at concentrations ranging from 0.1–50 μM for 24–72 hours. AMPK activation is assessed by measuring phosphorylation of AMPK and its downstream targets (e.g., ACC) by Western blot. GDF15 protein levels are measured by ELISA or Western blot. Cell viability and proliferation are evaluated by standard assays.
|
| Animal Protocol |
In vivo animal studies for AMPK activator 12 have not been reported in publicly available literature. The compound is primarily used for in vitro research. Future studies in animal models of cancer or metabolic diseases would be needed to evaluate in vivo efficacy. Standard protocols for AMPK activator studies could be adapted.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for AMPK activator 12 have not been published. The compound has a molecular weight of 426.35 and formula C23H24BrNO2. Solubility information is limited. In vivo PK parameters such as half-life, bioavailability, and tissue distribution have not been characterized. For in vivo use, formulation would need to be developed.
|
| Toxicity/Toxicokinetics |
Toxicology data for AMPK activator 12 have not been published. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been performed. Standard safety precautions for handling chemical activators should be observed.
|
| References | |
| Additional Infomation |
AMPK activator 12 (CAS: 431920-24-0, molecular formula C23H24BrNO2, molecular weight 426.35) is also known as compound 21. It is a potent AMPK activator and GDF15 inducer. It is not in clinical trials and has no regulatory approval. The compound is supplied as a research-grade activator for laboratory use only.
|
| Exact Mass |
425.099
|
|---|---|
| CAS # |
431920-24-0
|
| PubChem CID |
2910412
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
27
|
| Complexity |
368
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C=C1)CN(CC2=CC=CC=C2)CC(COC3=CC=C(C=C3)Br)O
|
| InChi Key |
WNGGJGGXJPRFJK-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C23H24BrNO2/c24-21-11-13-23(14-12-21)27-18-22(26)17-25(15-19-7-3-1-4-8-19)16-20-9-5-2-6-10-20/h1-14,22,26H,15-18H2
|
| Chemical Name |
1-(4-bromophenoxy)-3-(dibenzylamino)propan-2-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
